Production (Stage)
Knight Therapeutics Inc.
GUD.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 8.76% | 11.36% | 2.95% | 2.39% | 4.42% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.76% | 11.36% | 2.95% | 2.39% | 4.42% |
| Cost of Revenue | 11.19% | 10.32% | -0.86% | -4.65% | 5.67% |
| Gross Profit | 5.95% | 12.55% | 7.38% | 11.16% | 3.01% |
| SG&A Expenses | 13.75% | 16.84% | 2.96% | -1.06% | -4.92% |
| Depreciation & Amortization | -6.82% | -2.98% | -12.91% | -13.83% | -14.78% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.03% | 11.26% | -0.86% | -4.07% | -0.18% |
| Operating Income | -113.47% | 16.46% | 484.56% | 157.35% | 130.20% |
| Income Before Tax | 135.62% | 108.04% | -69.34% | 12.69% | 9.31% |
| Income Tax Expenses | 69.58% | 56.84% | 88.65% | 78.00% | 42.19% |
| Earnings from Continuing Operations | 161.52% | 123.95% | -305.02% | -34.85% | -16.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 161.52% | 123.95% | -305.02% | -34.85% | -16.72% |
| EBIT | -113.47% | 16.46% | 484.56% | 157.35% | 130.20% |
| EBITDA | -8.28% | 3.79% | 9.58% | 29.21% | 4.68% |
| EPS Basic | 162.16% | 124.96% | -421.67% | -54.56% | -33.69% |
| Normalized Basic EPS | 13.22% | 40.72% | 0.83% | 14,800.00% | 1,597.30% |
| EPS Diluted | 155.29% | 119.40% | -388.40% | -49.10% | -26.96% |
| Normalized Diluted EPS | 12.74% | 40.27% | 0.83% | 14,800.00% | 1,597.30% |
| Average Basic Shares Outstanding | -4.05% | -6.00% | -8.06% | -8.60% | -8.36% |
| Average Diluted Shares Outstanding | -3.95% | -6.01% | -8.16% | -8.61% | -8.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |